NASDAQ : BIAF
bioAffinity Technologies, Inc. — Key statistics
Healthcare · Diagnostics & Research · United States
Last price 2.91 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 3.73M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 3.86M |
| Enterprise Value | 2.87M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 1.28M |
| Shares Outstanding | 1.28M |
| Shares Change (YoY) | +578.55% |
| Shares Change (QoQ) | +16.29% |
| Owned by Insiders (%) | 6.63% |
| Owned by Institutions (%) | 4.36% |
| Float | 1.20M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.63 |
| Forward PS | 0.91 |
| PB Ratio | 0.35 |
| P/TBV Ratio | 2.23 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 0.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.44 |
| Quick Ratio | 1.24 |
| Debt / Equity | 0.38 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -276.15 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -1,860.15% |
| Return on Assets (ROA) | -125.11% |
| Return on Invested Capital (ROIC) | -414.08% |
| Return on Capital Employed (ROCE) | -250.72% |
| Weighted Average Cost of Capital (WACC) | -1.23% |
| Revenue Per Employee | $103,526 |
| Profits Per Employee | -$266,408 |
| Employee Count | 57 |
| Asset Turnover | 0.95 |
| Inventory Turnover | 61.08 |
Taxes
| Measure | Value |
|---|
| Income Tax | 6,363 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -1.25 |
| 52-Week Price Change | -91.86% |
| 50-Day Moving Average | 6.09 |
| 200-Day Moving Average | 19.16 |
| Relative Strength Index (RSI) | 35.04 |
| Average Volume (20 Days) | 1,955,862 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 66,654 |
| Short Previous Month | 115,467 |
| Short % of Shares Out | 5.20% |
| Short % of Float | 5.56% |
| Short Ratio (days to cover) | 0.02 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 5.90M |
| Gross Profit | 2.04M |
| Operating Income | -12.38M |
| Pretax Income | -15.18M |
| Net Income | -15.19M |
| EBITDA | -11.97M |
| EBIT | -12.38M |
| Loss Per Share | -$59.70 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 2.43M |
| Total Debt | 1.44M |
| Net Cash | 994,714 |
| Net Cash Per Share | $0.78 |
| Equity (Book Value) | 3.77M |
| Book Value Per Share | 8.34 |
| Working Capital | 1.18M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -11.47M |
| Capital Expenditures | -91,988 |
| Depreciation & Amortization | 413,093 |
| Net Borrowing | -248,167 |
| Free Cash Flow | -11.56M |
| FCF Per Share | -$9.01 |
Margins
| Measure | Value |
|---|
| Gross Margin | 34.61% |
| Operating Margin | -209.82% |
| Pretax Margin | -257.23% |
| Profit Margin | -257.33% |
| EBITDA Margin | -202.82% |
| EBIT Margin | -209.82% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -578.55% |
| Shareholder Yield | -578.55% |
| Earnings Yield | -1,983.23% |
| FCF Yield | -309.65% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 24, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -17.01 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |